• PBLS share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of PBLS shares has increased $0.85 since the market last closed. This is a 2.08% rise.

  • Closed at $41.73.

    The stock has since dropped $0.73 in after-hours trading.

Key terms

About PBLS

Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $5.16B

    A market capitalization between $2 billion and $10 billion places PBLS in the mid-capitalization category.

Key terms

Smart score

Latest PBLS news

Sep 17, 2026 5:00am ET Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Parabilis Medicines, Inc. (PBLS) and Acumen Pharmaceuticals (ABOS) by TipRanks Aug 25, 2026 9:15am ET Parabilis Medicines appoints Craig Tendler to board of directors by TipRanks Aug 17, 2026 4:05am ET Parabilis Medicines reports Q2 EPS ($2.32), consensus (24c) by TipRanks Aug 14, 2026 12:30pm ET Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) by TipRanks Aug 13, 2026 1:30pm ET Analysts Are Bullish on Top Healthcare Stocks: Parabilis Medicines, Inc. (PBLS), Cormedix (CRMD) by TipRanks Jul 24, 2026 12:33pm ET Parabilis Advances FOG-001 Trial in Tough Solid Tumors: What Investors Should Watch by TipRanks Jul 22, 2026 10:01pm ET Major Insider Move Signals Growing Confidence in Parabilis Medicines by TipRanks Jul 18, 2026 6:30am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Jul 16, 2026 8:36am ET Four new option listings on July 16th by TipRanks Jul 13, 2026 4:35am ET Parabilis Medicines, Inc. (PBLS) Receives a Buy from LifeSci Capital by TipRanks Jul 06, 2026 11:20am ET Analysts Offer Insights on Healthcare Companies: Parabilis Medicines, Inc. (PBLS) and LENZ Therapeutics (LENZ) by TipRanks Jul 06, 2026 11:16am ET Parabilis Medicines initiated with an Outperform at Leerink by TipRanks Jul 06, 2026 7:50am ET Parabilis Medicines initiated with an Outperform at Evercore ISI by TipRanks Jul 06, 2026 6:20am ET Parabilis Medicines initiated with a Buy at BofA by TipRanks Jul 06, 2026 6:05am ET Parabilis Medicines initiated with a Buy at Guggenheim by TipRanks Jul 06, 2026 5:56am ET Analyst Initiates Buy on Parabilis, Citing First-in-Class Wnt Inhibitor Zolucatidine and Strong Cash Runway by TipRanks Jul 06, 2026 5:55am ET Michael Schmidt Initiates Buy on Parabilis Medicines, Citing Helicon Platform and Zolucatetide as Key Value Drivers with $40 Price Target by TipRanks Jun 29, 2026 10:05pm ET Major Investor Makes Bold Move in Parabilis Medicines, Inc. Stock by TipRanks
Sep 01, 2026 7:00am ET Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference by GlobeNewswire Aug 25, 2026 7:00am ET Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors by GlobeNewswire Aug 13, 2026 7:00am ET Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates by GlobeNewswire Jun 11, 2026 4:05pm ET Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares by GlobeNewswire Jun 09, 2026 8:22pm ET Parabilis Medicines Announces Pricing of Upsized Initial Public Offering by GlobeNewswire

PBLS Financials

1-year income & revenue

  • PBLS total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • PBLS net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • PBLS earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

PBLS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

PBLS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    PBLS's competitors are included in the Health Technology sector and Pharmaceuticals: Major group

  • Market cap: $5.16B

    A market capitalization between $2 billion and $10 billion places PBLS in the mid-capitalization category.

Key terms

Latest investing news